Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.

Luspatercept significantly improved hemoglobin levels in non-transfusion-dependent patients with lower-risk myelodysplastic ...

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Did you know Robin Roberts’ openness about her health journey led to an astounding 1,800% increase in bone marrow donor ...

Huntsman Cancer Institute joins other institutions in myeloMATCH, a program that matches patients with clinical trials that ...

Panelists discuss how frontline luspatercept is emerging as an effective treatment for anemia in lower-risk myelodysplastic syndrome (LR-MDS), demonstrating significant improvements in hemoglobin ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials ...

Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelofibrosis (MF).

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.